Date: 2017-05-02
Type of information: Licensing agreement
Compound: lentiviral vector platform
Company: Bluebird bio (USA - MA) Novartis (Swtizerland)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: gene therapy
Disease:
Details:
- • On May 2, 2017, bluebird bio has entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis. Under the terms of the agreement with Novartis, Novartis will non-exclusively license certain bluebird patent rights related to lentiviral vector technology to develop and commercialize chimeric antigen receptor T cell (CAR T) therapies for oncology, including CTL019, Novartis’s anti-CD19 CAR T investigational therapy.
Financial terms: Financial terms of the agreement include an upfront payment to bluebird as well as milestone and royalty payments.
Latest news:
Is general: Yes
